HCPCS · Treatment J0897 Injection, denosumab, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 96.23M services · est. ▲ 4.0% YoY · 457,711 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 48.16M observed fee-for-service services

See the national market for J0897 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3262 Injection, tocilizumab, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 71.62M services · est. ▲ 21.3% YoY · 14,719 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 35.79M observed fee-for-service services

See the national market for J3262 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0174 Injection, lecanemab-irmb, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 65.37M services · est. ▲ 3374.2% YoY · 6,300 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 31.38M observed fee-for-service services

See the national market for J0174 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3111 Injection, romosozumab-aqqg, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 57.48M services · est. ▲ 40.0% YoY · 36,482 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 28.42M observed fee-for-service services

See the national market for J3111 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3380 Injection, vedolizumab, intravenous, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 16.65M services · est. ▲ 23.4% YoY · 12,322 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 8.33M observed fee-for-service services

See the national market for J3380 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1745 Injection, infliximab, excludes biosimilar, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 11.16M services · est. ▲ 3.3% YoY · 31,833 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 5.58M observed fee-for-service services

See the national market for J1745 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2357 Injection, omalizumab, 5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 7.65M services · est. ▲ 8.4% YoY · 12,050 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 3.85M observed fee-for-service services

See the national market for J2357 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2350 Injection, ocrelizumab, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2018 — first year this code appears in Part B claims

National scale 3.44M services · est. ▲ 1.0% YoY · 1,998 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.72M observed fee-for-service services

See the national market for J2350 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2182 Injection, mepolizumab, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2017 — first year this code appears in Part B claims

National scale 3.35M services · est. ▲ 8.8% YoY · 3,638 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.68M observed fee-for-service services

See the national market for J2182 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7170 Injection, emicizumab-kxwh, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 2.96M services · est. ▲ 10.0% YoY · 129 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.37M observed fee-for-service services

See the national market for J7170 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3245 Injection, tildrakizumab, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 2.55M services · est. ▲ 28.3% YoY · 5,255 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.28M observed fee-for-service services

See the national market for J3245 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3032 Injection, eptinezumab-jjmr, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 1.92M services · est. ▲ 67.8% YoY · 2,036 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 947,084 observed fee-for-service services

See the national market for J3032 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2323 Injection, natalizumab, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1.87M services · est. ▼ 20.8% YoY · 775 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 870,734 observed fee-for-service services

See the national market for J2323 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0640 Injection, leucovorin calcium, per 50 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1.24M services · est. ▲ 3.5% YoY · 13,693 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 629,119 observed fee-for-service services

See the national market for J0640 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3247 Injection, secukinumab, intravenous, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 1.09M services · est. · 745 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 531,540 observed fee-for-service services

See the national market for J3247 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0175 Injection, donanemab-azbt, 2 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 901,269 services · est. · 505 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 449,525 observed fee-for-service services

See the national market for J0175 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q5104 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2018 — first year this code appears in Part B claims

National scale 650,107 services · est. ▼ 36.9% YoY · 2,215 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 317,132 observed fee-for-service services

See the national market for Q5104 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0517 Injection, benralizumab, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 644,656 services · est. ▲ 11.4% YoY · 3,560 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 326,267 observed fee-for-service services

See the national market for J0517 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0490 Injection, belimumab, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 382,337 services · est. ▼ 8.4% YoY · 624 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 199,234 observed fee-for-service services

See the national market for J0490 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1303 Injection, ravulizumab-cwvz, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 121,920 services · est. ▲ 72.3% YoY · 36 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 60,810 observed fee-for-service services

See the national market for J1303 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1300 Injection, eculizumab, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 89,741 services · est. ▲ 21.1% YoY · 16 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 44,760 observed fee-for-service services

See the national market for J1300 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q5103 Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2018 — first year this code appears in Part B claims

National scale 88,598 services · est. ▲ 3.5% YoY · 284 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 43,056 observed fee-for-service services

See the national market for Q5103 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2329 Injection, ublituximab-xiiy, 1mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 75,834 services · est. · 49 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 36,750 observed fee-for-service services

See the national market for J2329 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3241 Injection, teprotumumab-trbw, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 72,016 services · est. ▼ 41.1% YoY · 55 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 32,292 observed fee-for-service services

See the national market for J3241 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q5121 Injection, infliximab-axxq, biosimilar, (avsola), 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 59,151 services · est. ▼ 24.7% YoY · 255 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 25,887 observed fee-for-service services

See the national market for Q5121 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q5135 Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 53,648 services · est. · 20 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 26,758 observed fee-for-service services

See the national market for Q5135 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3357 Ustekinumab, for subcutaneous injection, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 47,802 services · est. ▼ 84.8% YoY · 201 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 25,470 observed fee-for-service services

See the national market for J3357 → ranked groups · states · 12-yr trend

HCPCS · Treatment M0247 Intravenous infusion, sotrovimab, includes infusion and post administration monitoring CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 15,461 services · est. ▲ 362.4% YoY · 8,515 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 8,540 observed fee-for-service services

See the national market for M0247 → ranked groups · states · 12-yr trend

HCPCS · Treatment M0239 Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 13,552 services · est. ▲ 396.5% YoY · 7,640 FFS beneficiary-episodes (CY2021, all-Medicare estimate) — 7,822 observed fee-for-service services

See the national market for M0239 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3358 Ustekinumab, for intravenous injection, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2018 — first year this code appears in Part B claims

National scale 11,992 services · est. ▼ 74.0% YoY · 14 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 5,981 observed fee-for-service services

See the national market for J3358 → ranked groups · states · 12-yr trend

HCPCS · Treatment M0243 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 9,691 services · est. ▼ 92.2% YoY · 5,014 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 5,027 observed fee-for-service services

See the national market for M0243 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q0247 Injection, sotrovimab, 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 4,203 services · est. · 2,268 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 2,270 observed fee-for-service services

See the national market for Q0247 → ranked groups · states · 12-yr trend

HCPCS · Treatment M0248 Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 2,705 services · est. · 1,487 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 1,491 observed fee-for-service services

See the national market for M0248 → ranked groups · states · 12-yr trend

HCPCS · Treatment M0245 Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 2,478 services · est. ▼ 83.0% YoY · 1,229 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 1,231 observed fee-for-service services

See the national market for M0245 → ranked groups · states · 12-yr trend

HCPCS · Treatment M0244 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital duri CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 2,160 services · est. ▼ 87.3% YoY · 1,164 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 1,172 observed fee-for-service services

See the national market for M0244 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0565 Injection, bezlotoxumab, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 1,872 services · est. ▼ 29.7% YoY · 11 FFS beneficiary-episodes (CY2021, all-Medicare estimate) — 1,065 observed fee-for-service services

See the national market for J0565 → ranked groups · states · 12-yr trend

HCPCS · Treatment M0221 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 1,718 services · est. · 893 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 992 observed fee-for-service services

See the national market for M0221 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q0239 Injection, bamlanivimab-xxxx, 700 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 1,621 services · est. ▲ 2130.4% YoY · 941 FFS beneficiary-episodes (CY2021, all-Medicare estimate) — 947 observed fee-for-service services

See the national market for Q0239 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q0244 Injection, casirivimab and imdevimab, 1200 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 741 services · est. ▼ 93.2% YoY · 407 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 408 observed fee-for-service services

See the national market for Q0244 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q0245 Injection, bamlanivimab and etesevimab, 2100 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 625 services · est. ▼ 72.0% YoY · 314 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 314 observed fee-for-service services

See the national market for Q0245 → ranked groups · states · 12-yr trend

HCPCS · Treatment M0220 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 375 services · est. ▼ 99.2% YoY · 180 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 180 observed fee-for-service services

See the national market for M0220 → ranked groups · states · 12-yr trend

HCPCS · Treatment M0246 Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergen CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 317 services · est. · 171 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 172 observed fee-for-service services

See the national market for M0246 → ranked groups · states · 12-yr trend

HCPCS · Treatment M0240 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 181 services · est. ▼ 96.1% YoY · 95 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 95 observed fee-for-service services

See the national market for M0240 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q0243 Injection, casirivimab and imdevimab, 2400 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 158 services · est. ▼ 96.9% YoY · 95 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 95 observed fee-for-service services

See the national market for Q0243 → ranked groups · states · 12-yr trend

HCPCS · Treatment M0241 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital duri CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 103 services · est. · 56 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 56 observed fee-for-service services

See the national market for M0241 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q0240 Injection, casirivimab and imdevimab, 600 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 102 services · est. ▼ 95.3% YoY · 52 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 52 observed fee-for-service services

See the national market for Q0240 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q0220 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 45 services · est. ▼ 99.9% YoY · 23 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 23 observed fee-for-service services

See the national market for Q0220 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q0221 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 31 services · est. · 16 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 16 observed fee-for-service services

See the national market for Q0221 → ranked groups · states · 12-yr trend

Injection - Monoclonal Antibodies codes